Objective-17β-Estradiol (E2) offers cardiovascular protection in young female animals and postmenopausal women. In contrast, randomized trials of menopausal hormones performed in older women have shown harm or no cardiovascular benefit. We hypothesize that E2 effects on vascular inflammation are age dependent. Approach and Results-Young (10 weeks) and aged (52 weeks) female C57BL/6 mice were used as source for primary cultures of bone marrow-derived macrophages (BMMs) and vascular smooth muscle cells (VSMCs). E2 pretreatment of cells derived from young mice attenuated C-reactive protein (CRP)-induced expression of inflammatory mediators. In contrast, E2 pretreatment of cells from aged mice did not alter (BMMs) or paradoxically exaggerated (VSMCs) inflammatory mediator response to CRP. Using E2 receptor (ER) knockout mice, we demonstrated that E2 regulates inflammatory response to CRP in BMMs via ERα and in VSMCs via ERβ. BMMs derived from aged (versus young) mice expressed significantly less ERα mRNA and protein. A selective ligand of the novel ER GPR30 reproduced the E2 effects in BMMs and VSMCs. Unlike in young mice, E2 did not reduce neointima formation in ligated carotid arteries of aged CRP transgenic mice. Conclusions-E2 attenuates inflammatory response to CRP in BMMs and VSMCs derived from young but not aged mice and reduces neointima formation in injured carotid arteries of young but not aged CRP transgenic mice. ERα expression in BMMs is greatly diminished with aging. These data suggest that vasoprotective effects of E2 are age dependent and may explain the vasotoxic effects of E2 seen in clinical trials of postmenopausal women. (Arterioscler Thromb Vasc
I nflammation plays a major role in the pathogenesis of vascular disease, including atherosclerosis and the response to acute vascular injury. 1 In mechanistic studies, 17β-estradiol (E2), via engagement of E2 receptors (ERs), attenuates the inflammatory response to vascular injury. [2] [3] [4] [5] Further, observational studies indicate that postmenopausal women who choose to use hormone replacement therapy experience a significantly lower rate of cardiovascular disease (CVD) events than those who do not. 6 Clinical trials such as the Women's Health Initiative (WHI), however, reported an increase in CVD events in women treated with menopausal hormone therapy compared with those treated with placebo, calling into question the concept of estrogenic vasoprotection. 7 Importantly, the WHI enrolled older women than the observational studies. It has been hypothesized that E2 signaling pathways are altered with aging such that the anti-inflammatory/vasoprotective effects seen in premenopausal women are converted to proinflammatory/vasotoxic effects in women who are many years postmenopausal. [8] [9] [10] C-reactive protein (CRP) is a widely accepted blood marker for CVD risk in women. 11 Using young ovariectomized (OVX) CRP transgenic mice (CRPtg) that express human CRP in a manner that closely resembles the human condition, we have shown that CRP exacerbates the inflammatory response to vascular injury, 12, 13 and that E2 attenuates the inflammatory response and neointima formation induced by CRP in this model. 14 The role of age-related alterations in ER signaling in this model is not known. E2 exerts its anti-inflammatory effects in the vasculature via the traditional nuclear ERs, ERα and ERβ, and the more recently discovered G-protein-coupled receptor 30 (GPR30). [15] [16] [17] These ERs have distinct tissue distributions and functions. Because injury-induced vascular inflammation and remodeling are mediated by both activated macrophages and vascular smooth muscle cells (VSMCs), 15 we tested the hypothesis that E2 regulates CRP-induced inflammation in these cell types in an age-dependent manner and via different ERs.
Material and Methods
Materials and Methods are available in the online-only Supplement.
Results
To test the hypothesis that the vasoprotective effects of E2 observed in young OVX CRPtg subjected to carotid artery ligation 14 are lost in older mice, aged (50-54 weeks) CRPtg underwent OVX and subcutaneous implantation of pellets containing E2 or vehicle followed by carotid artery ligation 1 week later. In aged CRPtg, there was an ≈40% increase in intima formation in the E2-treated animals compared with vehicle controls (Figure 1 ). Although the comparison did not reach the level of statistical significance, the E2 effect is opposite what we observed earlier for similarly treated young OVX CRPtg, wherein E2 treatment resulted in ≈85% reduction in neointima formation. 14 Real-time quantitative reverse transcription polymerase chain reaction analysis of bone marrow-derived macrophages (BMMs) and VSMCs derived from young and aged C57BL/6 mice showed that proinflammatory mediators (CCL3, CCL4, IL-1, and C3 for BMMs; ICAM, VCAM, p-selectin, CCL-2, and IL-8 for VSMCs) were expressed at low levels in the vehicle-treated groups, and that mRNA levels increased markedly (5-to 20-fold for BMMs and 4-to 150-fold for VSMCs) in response to CRP treatment (Figure 2A and 2B ). In the absence of CRP, E2 did not affect the expression of inflammatory mediators in either group. E2 pretreatment significantly attenuated the CRP-induced increased expression of inflammatory mediators in BMMs ( Figure 2A ) and VSMCs ( Figure 2B ) derived from young mice. In contrast, E2 pretreatment of BMMs from aged mice did not significantly change the CRP-induced increase in inflammatory mediator expression ( Figure 2A ), and paradoxically, E2 enhanced rather than depressed CRP-induced upregulation of inflammatory mediators in VSMCs derived from aged mice ( Figure 2B ). Multiplex analysis confirmed that protein levels of inflammatory mediators increased in response to CRP in BMMs from both young and aged mice, and that E2 pretreatment significantly reduced these levels in BMMs derived from young but not aged mice ( Figure 2C) .
To test the hypothesis that the age-dependent influence of E2 on CRP-induced expression of proinflammatory mediators is ER dependent, BMMs and VSMCs were cultured from young female ERα −/− and ERβ −/− mice. E2 had no effect on CRP-induced CCL3 and CCL4 mRNA expression in BMMs derived from ERα −/− mice, but it attenuated the CRP effect in BMMs derived from ERβ −/− mice ( Figure 3A ). The E2 effect in ERβ KO is comparable with that seen in BMMs cultured from young mice that express both ERα and ERβ (Figure 2A) , indicating that the effect of E2 on CRP-induced mRNA expression of CCL3 and CCL4 in BMMs is mediated by ERα and not ERβ. Conversely, E2 attenuated CRP-induced ICAM and IL-8 mRNA expression in VSMCs derived from ERα −/− mice but had no effect on CRP-driven inflammatory mediator expression in VSMCs derived from ERβ −/− mice ( Figure 3B ).
The findings in VSMCs were consistent with the previous studies from our laboratory that demonstrated using E2 agonists and antagonists that E2 inhibits proinflammatory mediator expression in VSMCs through an ERβ-mediated mechanism. 4 To confirm the findings in BMMs, BMMs from young mice were pretreated with the selective ER downregulator ICI 182, 780, or vehicle for 2 hours followed by E2 for 24 hours. Cells were then treated with CRP or vehicle for 4 hours, and CCL3 and CCL4 mRNA expression was measured. Pretreatment with ICI completely blocked the inhibitory effect of E2 on CRP-induced expression of CCL3 and CCL4 ( Figure 4A ). After establishing the ER dependence of the E2 effect, we used selective ER agonists and antagonists to identify the specific ER subtype responsible. PPT, a selective ERα agonist, reproduced the effects previously seen with E2, whereas MPP, a selective ERα antagonist, completely blocked the E2 effect ( Figure 4B ). In contrast, DPN, a selective ERβ agonist, had no effect on CRP-induced expression of CCL4. These data confirm our findings in ER knockout mice that E2 acts through ERα and not ERβ on BMMs to abrogate CRPinduced mRNA expression of CCL4.
We then examined the effect of the selective GPR30 agonist G1 on CRP-mediated inflammation in BMMs and VSMCs. BMMs and VSMCs derived from young female mice were pretreated with G1 for 24 hours followed by CRP for 4 hours. Pretreatment with G1 significantly attenuated the CRPinduced increased expression of inflammatory mediators in BMMs ( Figure 4C ; CCL3, CCL4, and C3) and VSMCs ( Figure 4D ; ICAM, IL-8, and p-selectin) derived from young mice. However, in BMMs derived from aged mice, G1 but not E2 significantly inhibited CRP-derived inflammation ( Figure 4E ). Both G15 and G36 (GPR30 antagonists) had proinflammatory effects in our system. Therefore, we could not use these antagonists to address the hypothesis that blocking GPR30 will block the effects of E2 and G1 ( Figure I in the online-only Data Supplement).
ERα mRNA and protein were detectable in BMMs and VSMCs derived from C57BL/6 mice. In comparison with BMMs derived from young mice, BMMs from aged mice expressed 76±7% less ERα mRNA and 71±7% less ERα protein ( Figure 5A by VSMCs derived from aged mice was significantly higher than that in VSMCs from young animals, whereas ERα protein levels did not differ between groups ( Figure 5B ). BMMs and VSMCs derived from aged female mice expressed ERβ mRNA at a level similar to their young counterparts. We were unable to reliably measure ERβ protein levels because of limitations in currently available mouse ERβ antibodies. 18
Discussion
This study demonstrates for the first time that E2 regulates human CRP-induced inflammation in murine BMMs and VSMCs in an age-dependent manner; E2 inhibits inflammation in cells derived from young but not aged mice. Unlike in tumor necrosis factor-α-treated rat VSMCs, in which we have shown that the anti-inflammatory effect of E2 is mediated via ERβ using both selective agonists/antagonists 4 and ER knockout mice, we demonstrate that the effect of E2 on human CRPinduced inflammation in mouse BMMs is mediated via ERα and that expression of ERα on mouse BMMs is diminished with aging. We also show that G1, a selective GPR30 agonist, reproduces the anti-inflammatory effects of E2 in VSMCs and BMMs. Further, G1 suppresses the inflammatory response in BMMs derived from aged mice that are unresponsive to E2. These findings, if confirmed in humans, may help reconcile the seemingly paradoxical effects of E2 seen in clinical trials and could potentially define a subpopulation of women who may derive benefit from hormone therapy. Previous studies from our laboratory and others have shown that E2 has an anti-inflammatory effect in animal models of acute vascular injury. 15 In rodents, inflammatory cells, including macrophages, infiltrate the adventitia of the injured artery within hours of the insult. 5, 13 These inflammatory cells are attracted to and infiltrate the site of injury because of increased expression of inflammatory mediators by VSMCs in the medial domain of the artery. 3 Administration of E2 to OVX rodents attenuates expression of inflammatory mediators and the resultant infiltration of inflammatory cells into injured carotid arteries, limiting the neointimal response to vascular injury. 3, 5, 14 In vitro studies showed that E2 inhibits inflammation in rat VSMCs by 2 distinct mechanisms: (1) enhancing expression of IκBα, a direct inhibitor of NFκB activation, thus accelerating a negative feedback loop in NFκB signaling, and (2) directly inhibiting binding of NFκB to promoters of inflammatory genes, thereby inhibiting their expression. 19 The effect of E2 on inflammation may be context dependent. A recent study by Calippe et al 20 demonstrated that E2 treatment, via ERα activation in macrophages in vivo, enhances their ability to produce inflammatory mediators and cytokines on subsequent toll-like receptor activation. In the current study, E2 treatment of isolated BMMs and VSMCs derived from young female mice inhibited the CRP-induced inflammatory response of the cells. These data provide mechanistic insights into how E2 protects the vasculature of young female CRPtg against inflammation and adverse remodeling in response to acute vascular injury. Neointima formation in the carotid artery ligation model closely resembles that seen after reconstructive procedures such as angioplasty, vascular stenting, vascular grafts, and vein grafts. The model also offers an excellent opportunity to study vascular inflammation in response to acute injury, an essential component of all vascular diseases. Furthermore, because BMMs and VSMCs are intimately involved in many disease processes (eg, atherosclerosis), the findings could have wider implications than those studied here.
Observational studies in humans show benefit associated with E2 in women who choose to use menopausal hormones. In the Nurses' Health Study, which followed 70 533 postmenopausal women for up to 20 years and documented 1,258 major coronary events (nonfatal myocardial infarction or fatal coronary disease), current use of hormone therapy resulted in a multivariate adjusted relative risk of 0.61 (95% confidence interval, 0.52-0.71) compared with never users. 6 However, randomized controlled trials, such as WHI and Heart and Estrogen/progestin Replacement Study, have shown harm, or at least no benefit, of menopausal hormone treatment on CVD events. 7, 21, 22 The reason for this apparent paradox is not fully understood, but several explanations have been proposed, including the formulation used (conjugated equine estrogen versus E2), dose, route of administration (oral versus transdermal), duration of use, the potential deleterious effect of medroxyprogesterone acetate on the vasculature, the presence of comorbidities and pre-existing vascular disease, and the timing of E2 administration relative to onset of menopause and age. 10, 23, 24 The intriguing "timing hypothesis" proposes that the effect of E2 administration on the vasculature is dependent on the age and hormonal milieu of the recipient. 8, 9 Indeed, age has been shown to be an important determinant of the vascular effects of E2 in women, with beneficial effects observed in the early postmenopausal years but not in older (≥60 years) postmenopausal women. 25 In observational studies, and in real life, women generally start menopausal hormones in the perimenopausal or early postmenopausal period, whereas randomized, controlled trials enrolled women with an average age of 63 to 67 years. 6, 7, 21, 22 Subgroup analysis of one of these studies, the WHI, showed that when hormone therapy was initiated at a young age (50-59 years), it was associated with reduced risk of CVD. 26, 27 These findings were recently confirmed in the Danish Osteoporosis Prevention Study that randomized 1006 younger women (mean age 50 years) to receive hormone therapy versus no therapy. After 10 years of treatment, hormone therapy was associated with 52% reduction in the primary end point of death, myocardial infarction, or heart failure. 28 Interestingly, even in this relatively young population, an age effect was evident (relative risk = 0.35 for <50 years versus relative risk = 0.63 for ≥50 years). Our laboratory has previously shown that aged OVX rats subjected to balloon injury of the carotid artery lose the vasoprotective and anti-inflammatory responses to exogenous E2 seen in younger animals. 29 We confirmed here this age-dependent attenuation of the E2 effect in aged CRPtg subjected to ligation injury of the carotid artery. Further, we explored the effect of age on the actions of E2 on the 2 cell types central to the mouse carotid ligation model of vascular injury. Macrophages 30 and VSMCs 31 have been shown to express ERs, and E2 has been shown to inhibit the expression of proinflammatory mediators in macrophages 32 and VSMCs 4 derived from young animals. Unlike in cells derived from young animals, E2 treatment of BMMs and VSMCs derived from aged mice either did not attenuate (BMMs) or exacerbated (VSMCs) CRP-induced inflammation. In vivo, we have previously demonstrated that E2 inhibits CRP-mediated vascular remodeling in young CRPtg, 14 and we demonstrate here that this effect is lost and may be reversed in aged animals. These data support the concept that E2 modulates the vascular inflammatory response in an age-dependent manner and may help explain the lack of benefit of E2 treatment in clinical trials in elderly postmenopausal women. It is plausible that the findings reported here are related to prolonged deprivation from physiological levels of E2 in aged mice rather than aging itself. We did not directly measure E2 levels in our mice because of limitations of the available assays, which are unable to differentiate serum E2 levels between OVX and intact animals. 33 However, uterine weight was significantly lower in aged compared with young mice (62±11 versus 119±15 mg, P<0.05), suggesting E2 deprivation. Prior studies using different models have demonstrated that the anti-inflammatory effects of E2 are lost after an extended period of hypoestrogenicity. 34, 35 The effects of age versus time from menopause (or OVX) as a determinant of E2-induced modulation of vascular inflammation and remodeling in response to acute or chronic injury is an important topic for future basic and translational studies.
The anti-inflammatory/vasoprotective effects of E2 in vascular injury are known to be ER mediated, 15 but the specific ER subtype(s) responsible for these effects have been the subject of controversy. Studies in knockout mice demonstrated that ERα, but not ERβ, mediates the facilitatory effects of E2 on re-endothelialization after electric vascular injury. 36 Krom et al 37 used selective ERα and ERβ agonists and antagonists in a mouse model of vascular injury to show that local activation of ERβ with DPN inhibited neointima formation in a dose-dependent manner, whereas ERα activation using PPT inhibited the formation of neointima at low but not high doses.
The effects of E2 and DPN on neointima formation were not blocked with the ERα selective antagonist MPP, supporting their ERβ dependence. Thus, both ER subtypes seem to contribute to vasoprotection in murine models. We show here that E2 inhibits proinflammatory mediator expression in both BMMs and VSMC, and that its effects in BMMs are mediated via ERα and in VSMC via ERβ. These data taken together indicate that the effects of systemic E2 treatment on the vasculature are mediated via different ER subtypes expressed by different cell types.
In addition to the classical ERs, GPR30 has been identified as an important ER that mediates many estrogenic effects on the vasculature. 16 G1, a selective GPR30 agonist, reproduced the anti-inflammatory effects of E2 in VSMC and BMMs derived from young mice. Interestingly, G1 also exhibited anti-inflammatory effects in BMMs derived from aged mice in which E2 had no effect ( Figure 4E ). Further, E2 did not have anti-inflammatory effects in ERα knockout BMMs or ERβ knockout VSMCs (Figure 3 ). These observations are consistent with results of recent studies demonstrating that G1 may have GPR30-independent activities, 38 or alternatively, with findings of functional cross talk between the traditional ERs and GPR30, as suggested by other reports. 16, 39 These exciting findings may reveal new therapeutic targets for vasoprotection that are effective in aging women. The cellular mechanisms responsible for the decrease in E2-induced vasoprotection seen with aging are poorly understood. A limited number of studies have examined the effect of aging on ER expression in the vasculature. In an early study that was not able to differentiate ER subtypes, coronary arteries from postmenopausal women tended to have fewer ERs than those of premenopausal women, independent of the presence of atherosclerosis. 40 In a more recent study, ERα levels were decreased in endothelial cells from postmenopausal versus premenopausal women, and ERα expression was strongly related to endothelial function. 41 Consistent with our observation that the inhibitory effect of E2 on CRP-induced inflammation in BMMs is ERα dependent, we demonstrated that macrophages derived from aged mice expressed significantly less ERα than those derived from young mice. This novel finding may help explain why E2 administration is vasoprotective in young animal models of CVD and in young perimenopausal women but increases risk of CVD in older postmenopausal women. The change in expression of ERα with aging could be regulated by epigenetic modification of the gene promoter. For example, variation in methylation-associated inactivation of ER gene promoters in various tissue types, including in the cardiovascular system, has been described in aging rodents and humans. 42, 43 The hypermethylation of ERα with aging is more impressive when taken in context of the global hypomethylation of the genome that accompanies the aging process. 44 It is important to mention that the observed changes in ERα expression with aging are cell-type specific because they are not seen in VSMCs, and that age-dependent change in ERα expression does not account for the paradoxical effect of E2 on CRP-induced inflammatory mediator expression in VSMCs. We were not able to explore whether ERβ levels are decreased in VSMCs with aging because of the limitations in available antibodies to this receptor in the mouse. 18 Several limitations apply to our work. First, we recognize the limitations of using pharmacological ER agonists and antagonists to delineate biological processes. To optimize selectivity, we have performed dose-response analyses 4 and have used the lowest effective doses of these agents. We verified our results using cells derived from ER knockout animals. We note that the ERα knockout mouse that we have used has been shown to have residual E2 binding to uterine tissue, likely attributable to a truncated ERα isoform. [45] [46] [47] Therefore, we cannot exclude the possibility that residual ERα activity in our mouse model may have been responsible for the nonsignificant trend for E2 effect in Figure 3A . Further, we have not dissected the mechanism by which E2 inhibits inflammation in our cells. Because the effects of CRP in our model are attributed to its activation of immunoglobulin G Fc receptors (FcγRs), 12 the observation that E2, via its interaction with ERs, influences expression of FcγRs on the surface of macrophages 48 may partially explain the effect of E2 on CRP-mediated vascular inflammation seen in our study. However, because the anti-inflammatory effects of E2 seen in BMMs and VSMCs are not restricted to CRP-induced inflammation but are also evident in tumor necrosis factor-αinduced inflammation (Figures II and III in the online-only Data Supplement), the mechanism is more likely to involve a common downstream pathway (eg, at level of NFκB as described earlier).
In conclusion, the current study reveals that the antiinflammatory effects of E2 seen in BMMs and VSMCs derived from young female mice and in injured carotid arteries of young mice are lost with aging. G1, a GPR30 agonist, reproduced the effects of E2 in BMMs and VSMCs. E2 lost it anti-inflammatory effect in BMMs derived from ERα −/− and in VSMCs from ERβ −/− . ERα expression in BMMs is greatly diminished with aging. These results may help explain the lack of benefit of E2 treatment seen in clinical trials of menopausal hormone therapy and pave the way for novel therapeutic interventions that are tailored to preserve E2 responsiveness in aging vascular cells.
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